{"nctId":"NCT02701764","briefTitle":"Can Pregabalin Reduce the Frequency and Severity of Dry Eye Symptoms After Laser-assisted in Situ Keratomileusis?","startDateStruct":{"date":"2016-07-26","type":"ACTUAL"},"conditions":["Dry Eye"],"count":43,"armGroups":[{"label":"Pregabalin","type":"EXPERIMENTAL","interventionNames":["Drug: Pregabalin"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Pregabalin","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* 18 and 65 years of age\n* undergoing LASIK (unilateral or bilateral procedure).\n* Females of child-bearing age will need a negative urine or serum pregnancy test at the screening visit.\n* ocular and systemic medication regimen has been stable for 3 months\n\nExclusion Criteria:\n\n* Pregnant or lactating, participating in another study with an investigational drug within one month prior to screening\n* Using gabapentin, pregabalin, anti-convulsants, duloxetine, venlafaxine (SNRI), or tri-cyclic antidepressants\n* have a history of allergic, anaphylactic reaction, or severe systemic response to pregabalin or gabapentin\n* use corticosteroids chronically or during the month prior to surgery, or have a history of corneal disease (HSV or varicella zoster keratitis, prior corneal incisions (cataract surgery, radial keratotomy, LASIK), prior corneal ulcer).\n* patients with systemic co-morbidities that may confound DE such as HIV, sarcoidosis, graft-versus host disease or a collagen vascular disease.\n* Adults unable to consent\n* Individuals who are not yet adults (infants, children, teenagers)\n* Prisoners","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Severity of Dry Eye Symptoms as Assessed by the Dry Eye Questionnaire - 5 (DEQ5)","description":"DEQ5 total score ranges from 0-22 with the higher scores indicating increased dry eye. Absolute score will be reported from DEQ5 questionnaire completed at 6 month visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.6","spread":"5.0"},{"groupId":"OG001","value":"4.5","spread":"4.2"}]}]}]},{"type":"SECONDARY","title":"Dry Eye Symptoms as Evaluated by the Ocular Surface Disease Index (OSDI)","description":"OSDI total score ranges from 0-100 with a higher score indicating greater disability. Absolute scores will be reported from OSDI questionnaire completed at 3 and 6 month visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.9","spread":"11.5"},{"groupId":"OG001","value":"11.0","spread":"16.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.6","spread":"15.0"},{"groupId":"OG001","value":"12.3","spread":"16.8"}]}]}]},{"type":"SECONDARY","title":"Tear Production Measured by Schirmers Score","description":"Tear production will be measured via Schirmers score. Schirmer strips will be placed in the outer 1/3 of the lower conjunctivae. The Schirmer score will be evaluated as the length of wetting in mm in the Schirmer strips after 5 minutes. Absolute scores will be reported for the tear production evaluation at the 3 and 6 months visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.40","spread":"8.71"},{"groupId":"OG001","value":"15.90","spread":"9.32"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.45","spread":"8.17"},{"groupId":"OG001","value":"15.05","spread":"8.64"}]}]}]},{"type":"SECONDARY","title":"Tear Evaporation Measured by Tear Break up Time (TBUT)","description":"Participant will have 5 Î¼l of preservative free fluorescein placed on their eye. The participant will then be positioned in the head rest of the slit lamp instrument and will be instructed to blink three times naturally and then not blink. The integrity of the tear film will be measured and, using a stopwatch, the time from the last blink until one or more black (dry) spots appear in the precorneal tear film will be recorded as TBUT. The absolute scores for TBUT completed on the 3 and 6 month visit will be reported.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.10","spread":"3.87"},{"groupId":"OG001","value":"9.54","spread":"5.58"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.35","spread":"2.46"},{"groupId":"OG001","value":"9.05","spread":"5.93"}]}]}]},{"type":"SECONDARY","title":"Eye Pain as Evaluated by the Neuropathic Pain Symptom Inventory - Eye (NPSI-E)","description":"NPSI-E total score ranges from 0-100 with a higher score indicating increased eye pain. Absolute scores will be reported from NPSI-Eye questionnaire completed at 3 and 6 month visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.70","spread":"4.55"},{"groupId":"OG001","value":"1.86","spread":"4.07"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.81","spread":"4.07"},{"groupId":"OG001","value":"3.14","spread":"5.85"}]}]}]},{"type":"SECONDARY","title":"Eye Pain as Assessed by the Short Form - McGill Pain Questionnaire (Sf-MPQ) Sensory","description":"sf-MPQ Sensory has a total score ranging from 0-33 with a higher score indicating increased pain. Absolute scores will be reported from sf-MPQ Sensory questionnaire completed at 3 and 6 month visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.65","spread":"1.23"},{"groupId":"OG001","value":"0.36","spread":"0.66"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.48","spread":"1.03"},{"groupId":"OG001","value":"0.81","spread":"2.42"}]}]}]},{"type":"SECONDARY","title":"Eye Pain as Assessed by the Short Form - McGill Pain Questionnaire (Sf-MPQ) Affective","description":"sf-MPQ Affective has a total score ranging from 0-12 with a higher score indicating increased pain. Absolute scores will be reported from sf-MPQ Affective questionnaire completed at 3 and 6 month visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.30","spread":"0.66"},{"groupId":"OG001","value":"0.18","spread":"0.39"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.29","spread":"0.46"},{"groupId":"OG001","value":"0.43","spread":"0.98"}]}]}]},{"type":"SECONDARY","title":"Eye Pain as Assessed by the Numeric Rating Scale (NRS)","description":"NRS total score ranges from 0-10 over a one week recall period with the higher score indicating increased pain. Absolute scores will be reported from NRS questionnaire completed at 3 and 6 month visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.85","spread":"0.27"},{"groupId":"OG001","value":"0.27","spread":"0.55"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.10","spread":"1.48"},{"groupId":"OG001","value":"0.38","spread":"0.97"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":21},"commonTop":["Tiredness","Dizziness","Bloating","Headache","High or elevated mood"]}}}